About: Gedatolisib

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Gedatolisib (PF-05212384) is an experimental drug for treatment of cancer in development by Celcuity, Inc. The mechanism of action is accomplished by binding the different p110 catalytic subunit isoforms of PI3K and the kinase site of mTOR. The drug was originally developed by Wyeth, which Pfizer acquired in 2009. Gedatolisib is under development for patients with and without PIK3CA mutations.

Property	Value
dbo:abstract	Gedatolisib (PF-05212384) is an experimental drug for treatment of cancer in development by Celcuity, Inc. The mechanism of action is accomplished by binding the different p110 catalytic subunit isoforms of PI3K and the kinase site of mTOR. The drug was originally developed by Wyeth, which Pfizer acquired in 2009. Gedatolisib is under development for patients with and without PIK3CA mutations. (en)
dbo:casNumber	1197160-78-3
dbo:fdaUniiCode	96265TNH2R
dbo:kegg	D10635
dbo:pubchem	44516953
dbo:thumbnail	wiki-commons:Special:FilePath/Gedatolisib.svg?width=300
dbo:wikiPageExternalLink	https://www.sec.gov/Archives/edgar/data/1603454/000165495421003990/celc_ex993.htm
dbo:wikiPageID	55206143 (xsd:integer)
dbo:wikiPageLength	9442 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1115028124 (xsd:integer)
dbo:wikiPageWikiLink	dbr:MTORC1 dbr:Breast_cancer dbc:Pfizer_brands dbc:Triazines dbc:Ureas dbr:Colorectal_cancer dbr:PI3K/AKT/mTOR_pathway dbr:Endometrial_cancer dbc:Experimental_cancer_drugs dbr:MTOR dbr:Acute_myeloid_leukemia dbc:Benzamides dbr:Cell_proliferation dbc:Morpholines dbc:Phosphoinositide_3-kinase_inhibitors dbr:Wyeth dbr:Experimental_drug dbr:P110α dbr:PI3K dbr:PIK3CA
dbp:c	32 (xsd:integer)
dbp:casNumber	1197160 (xsd:integer)
dbp:h	41 (xsd:integer)
dbp:iupacName	1 (xsd:integer)
dbp:kegg	D10635 (en)
dbp:n	9 (xsd:integer)
dbp:o	4 (xsd:integer)
dbp:pubchem	44516953 (xsd:integer)
dbp:smiles	CNC1CCNCC2=CC=CNCNC3=CC=CC4=NCN6CCOCC6 (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	DWZAEMINVBZMHQ-UHFFFAOYSA-N (en)
dbp:synonyms	PF-05212384;PKI-587 (en)
dbp:unii	96265 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Infobox_drug dbt:Reflist dbt:USGovernment
dcterms:subject	dbc:Pfizer_brands dbc:Triazines dbc:Ureas dbc:Experimental_cancer_drugs dbc:Benzamides dbc:Morpholines dbc:Phosphoinositide_3-kinase_inhibitors
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug
rdfs:comment	Gedatolisib (PF-05212384) is an experimental drug for treatment of cancer in development by Celcuity, Inc. The mechanism of action is accomplished by binding the different p110 catalytic subunit isoforms of PI3K and the kinase site of mTOR. The drug was originally developed by Wyeth, which Pfizer acquired in 2009. Gedatolisib is under development for patients with and without PIK3CA mutations. (en)
rdfs:label	Gedatolisib (en)
owl:sameAs	wikidata:Gedatolisib https://global.dbpedia.org/id/2XxhQ
prov:wasDerivedFrom	wikipedia-en:Gedatolisib?oldid=1115028124&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Gedatolisib.svg
foaf:isPrimaryTopicOf	wikipedia-en:Gedatolisib
is dbo:wikiPageWikiLink of	dbr:MTORC1 dbr:Phosphoinositide_3-kinase_inhibitor
is foaf:primaryTopic of	wikipedia-en:Gedatolisib